In the phase I/II CHRYSALIS trial, gilteritinib demonstrated promising results as monotherapy in R/R FLT3-mutant AML with an overall response rate (ORR) of 40% and a median OS of 25 weeks (52). The gene discussed is FLT3; the disease is acute myeloid leukemia.